JP2002512199A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002512199A5 JP2002512199A5 JP2000544345A JP2000544345A JP2002512199A5 JP 2002512199 A5 JP2002512199 A5 JP 2002512199A5 JP 2000544345 A JP2000544345 A JP 2000544345A JP 2000544345 A JP2000544345 A JP 2000544345A JP 2002512199 A5 JP2002512199 A5 JP 2002512199A5
- Authority
- JP
- Japan
- Prior art keywords
- opg
- amino
- polypeptide
- region
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 35
- 150000001413 amino acids Chemical group 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 17
- 229920001184 polypeptide Polymers 0.000 description 16
- 102000004196 processed proteins & peptides Human genes 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 235000018417 cysteine Nutrition 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000006386 Bone Resorption Diseases 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000052781 human TNFRSF11B Human genes 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 208000005475 Vascular calcification Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/064,832 | 1998-04-23 | ||
| US09/064,832 US6790823B1 (en) | 1998-04-23 | 1998-04-23 | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| PCT/US1999/008793 WO1999053942A1 (en) | 1998-04-23 | 1999-04-21 | Compositions comprising osteoprotegerin for the prevention and treatment of cardiovascular diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002512199A JP2002512199A (ja) | 2002-04-23 |
| JP2002512199A5 true JP2002512199A5 (OSRAM) | 2009-12-17 |
| JP4776774B2 JP4776774B2 (ja) | 2011-09-21 |
Family
ID=22058524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000544345A Expired - Fee Related JP4776774B2 (ja) | 1998-04-23 | 1999-04-21 | 心血管疾患の予防及び治療用オステオプロテゲリン含有組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6790823B1 (OSRAM) |
| EP (1) | EP1073456B1 (OSRAM) |
| JP (1) | JP4776774B2 (OSRAM) |
| AT (1) | ATE303817T1 (OSRAM) |
| AU (1) | AU757806B2 (OSRAM) |
| CA (1) | CA2325360C (OSRAM) |
| DE (1) | DE69927147T2 (OSRAM) |
| DK (1) | DK1073456T3 (OSRAM) |
| ES (1) | ES2248998T3 (OSRAM) |
| SI (1) | SI1073456T1 (OSRAM) |
| WO (1) | WO1999053942A1 (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
| EP0946725B1 (en) | 1996-12-23 | 2011-01-26 | Immunex Corporation | Receptor activator of nf-kappa b, receptor is member of tnf receptor superfamily |
| ATE328006T1 (de) | 1997-04-15 | 2006-06-15 | Sankyo Co | Neues protein und verfahren zu dessen herstellung |
| SI0975754T2 (sl) | 1997-04-16 | 2016-04-29 | Amgen Inc., | Vezivni proteini in receptorji osteoprotegerina |
| US6316408B1 (en) | 1997-04-16 | 2001-11-13 | Amgen Inc. | Methods of use for osetoprotegerin binding protein receptors |
| JP4380067B2 (ja) * | 1998-04-23 | 2009-12-09 | 味の素株式会社 | 抗血栓活性物質及びグリコカリシンの検出法 |
| ATE412746T1 (de) | 1998-05-14 | 2008-11-15 | Immunex Corp | Verfahren zur hemmung der wirkung der osteoklasten |
| WO2002081521A2 (en) * | 2001-04-03 | 2002-10-17 | Société des Produits Nestlé S.A. | Osteoprotegerin in milk |
| US7198798B2 (en) * | 2001-05-10 | 2007-04-03 | University Of Washington | Methods and devices for promoting endothelial morphogenesis |
| MXPA03010747A (es) | 2001-05-25 | 2004-03-02 | Human Genome Sciences Inc | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. |
| US8649843B2 (en) * | 2001-11-24 | 2014-02-11 | Ben A. Arnold | Automated calcium scoring of the aorta |
| CA2481074A1 (en) | 2002-04-05 | 2003-10-23 | Amgen Inc. | Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors |
| JP4430403B2 (ja) * | 2002-04-10 | 2010-03-10 | メルク セローノ ソシエテ アノニム | 線維化疾患の治療および／または予防のためのオステオプロテゲリンの使用 |
| US7585840B2 (en) | 2002-04-10 | 2009-09-08 | Merck Serono S.A. | Use of osteoprotegerin for the treatment and/or prevention of fibrotic disease |
| EP1807436B1 (en) | 2004-10-25 | 2014-06-18 | Intezyne Technologies Inc. | Heterobifunctional poly(ethylene glycol) and uses thereof |
| NZ598887A (en) | 2005-01-04 | 2013-06-28 | Intezyne Technologies Inc | A method for preparing a multi-block copolymer |
| US7561727B2 (en) * | 2005-06-02 | 2009-07-14 | Nordic Bioscience Imaging A/S | Method of deriving a quantitative measure of a degree of calcification of an aorta |
| US7463758B2 (en) * | 2005-06-02 | 2008-12-09 | Nordio Bioscience A/S | Method of deriving a quantitative measure of a degree of calcification of an aorta |
| EP2433644A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer therapeutics |
| FR2970870A1 (fr) * | 2011-01-31 | 2012-08-03 | Centre Nat Rech Scient | Modulation de la proliferation des cellules epitheliales de l'unite epidermo-pilo-sebacee via rank |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
| AU648505B2 (en) | 1989-05-19 | 1994-04-28 | Amgen, Inc. | Metalloproteinase inhibitor |
| US5580722A (en) * | 1989-07-18 | 1996-12-03 | Oncogene Science, Inc. | Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
-
1998
- 1998-04-23 US US09/064,832 patent/US6790823B1/en not_active Expired - Fee Related
-
1999
- 1999-04-21 AU AU36605/99A patent/AU757806B2/en not_active Ceased
- 1999-04-21 ES ES99918766T patent/ES2248998T3/es not_active Expired - Lifetime
- 1999-04-21 AT AT99918766T patent/ATE303817T1/de active
- 1999-04-21 SI SI9930826T patent/SI1073456T1/sl unknown
- 1999-04-21 JP JP2000544345A patent/JP4776774B2/ja not_active Expired - Fee Related
- 1999-04-21 EP EP99918766A patent/EP1073456B1/en not_active Expired - Lifetime
- 1999-04-21 DE DE69927147T patent/DE69927147T2/de not_active Expired - Lifetime
- 1999-04-21 WO PCT/US1999/008793 patent/WO1999053942A1/en not_active Ceased
- 1999-04-21 CA CA002325360A patent/CA2325360C/en not_active Expired - Fee Related
- 1999-04-21 DK DK99918766T patent/DK1073456T3/da active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002512199A5 (OSRAM) | ||
| JP4659068B2 (ja) | Ｏｂ融合タンパク質組成物および方法 | |
| CN1318588C (zh) | 促骨生长素 | |
| EP0975771B1 (en) | Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins | |
| Force et al. | Mouse lymphotoxin-beta receptor. Molecular genetics, ligand binding, and expression | |
| US7112659B2 (en) | OB fusion protein compositions and methods | |
| JP2868777B2 (ja) | ヒトマンノース結合タンパク質 | |
| JPH11501208A (ja) | 抗肥満症タンパク質 | |
| CA2082052A1 (en) | Mammalian expression of the bmp-2 family | |
| JP2005509409A (ja) | 糖尿病および他の血糖疾患の治療方法 | |
| HU211348A9 (en) | Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis | |
| CA2358862A1 (en) | Methods of increasing lean tissue mass using ob protein compositions | |
| JP2013028622A (ja) | オステオプロテゲリン結合性蛋白および受容体 | |
| JPH11501297A (ja) | 抗肥満症タンパク質 | |
| KR20150111347A (ko) | 듀켄씨 근이영양증의 치료에서의 폴리스타틴 | |
| JP2006502702A5 (OSRAM) | ||
| JP2009510999A (ja) | キメラ治療剤 | |
| JP2002533115A5 (OSRAM) | ||
| EP1001768A1 (en) | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor | |
| JP2005512509A5 (OSRAM) | ||
| KR19980064258A (ko) | 항비만 단백질 | |
| JPH1156378A (ja) | 変異型ヒト成長ホルモンとその用途 | |
| HK1021388B (en) | Ob fusion protein compositions and methods | |
| JP2002508170A (ja) | 哺乳動物カルシトニン様ポリペプチド−１ | |
| AU2004202448A1 (en) | OB Fusion Protein Compositions and Methods |